PPAR-γ agonists have been shown to decrease insulin resistance by increasing the capacity of fat cells to store lipids (20) and to augment adiponectin expression, which contributes to a lower risk of insulin resistance (21). The gene discussed is ADIPOQ; the disease is Insulin resistance.